Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genmab, a biotechnology company, has announced a milestone payment of DKK20m is triggered in relation to filing of the new drug application (NDA) to the Japanese Ministry of Health, Labor and Welfare (MHLW) for Arzerra.
Subscribe to our email newsletter
Genmab gained the payment from GlaxoSmithKline which was triggered by the NDA submission of Arzerra.
The application seeks approval for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received prior therapy.
According to Genmab, the announcement does not affect its financial guidance for 2012.
Genmab is a publicly traded company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.